Abstract 1833
Background
Although the personalized medicine has always focused on the genomic or proteomic characterization of tumor, medical imaging is still one of the major factors to guide therapy and to monitor the progression of the tumor. Radiomics is an emerging field that converts the medical image data into the mineable quantitative features via the automatically algorithms, and can server as a bridge between medical image, genomics and clinical-parameters. Serval studies have demonstrated that the radiomic-based model can predict outcome of RCC, but the correlation between radiomic features and histological subtypes of RCC is still unknown. The aim of this letter is to focus on the ability of radiomics to identify the histological subtypes and metastasis of RCC.
Methods
This study included Forty-four patients diagnosed with renal tumor. For each renal lesion, The CT images of volume of interest (VOI) were obtained semi-automatically by two experienced nuclear medicine physician, 85 texture features were extracted from each VOI using the first-order statistics features, Shape Based Features, Gray Level Neighboring Gray Level Dependence Matrix and Neighboring Gray Tone Difference Matrix.
Results
To investigate the value of radiomic features to capture phenotypic differences of RCC, we performed Unsupervised Clustering of patients with similar radiomic expression patterns. We analyzed the two main clusters of patients with clinical parameters, and found that the tumor clusters were statistically and significantly associated with primary tumor stage (P < 0.001), M-stage (P = 0.049) and benign (P = 0.037), wherein high T-stages, M-stage and tumor group showed in cluster II. RCC histology and N-stage (lymph-node) did not reach statistical significance for their association with the radiomic expression patterns (P = 0.165, 0.361, respectively). In addition, we analyzed the overall survival (OS) of the each radiomic features, and showed that P25, IMC1 and IMC2 were associated with OS (P = 0.002, 0.002, 0.016, respectively, log-rank test).
Conclusions
The radiomic features from medical images could be helpful in deciphering T-stages, metastasis and benign of RCC and may have potential as imaging biomarker for prediction of RCC overall survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhejiang Cancer Hospital.
Funding
National Natural Science Foundation of China (No 81402117, 81671775), Natural Science Foundation of Zhejiang Province (No LY17H160043) and Qianjiang talent plan of Zhejiang Province (No QJD1602025).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5056 - Phase 2 study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
5710 - Avelumab for advanced Merkel cell carcinoma in the Netherlands; a nationwide survey
Presenter: Sonja Levy
Session: Poster Display session 3
Resources:
Abstract
3152 - Health-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow-up data
Presenter: Sandra D'Angelo
Session: Poster Display session 3
Resources:
Abstract
5715 - A Phase 2, Randomized Study of Nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and Stereotactic Body Radiation Therapy (SBRT) for Metastatic Merkel Cell Carcinoma (MCC, NCT03071406) – a preliminary report.
Presenter: Sungjune Kim
Session: Poster Display session 3
Resources:
Abstract
2854 - Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma
Presenter: Kalijn Bol
Session: Poster Display session 3
Resources:
Abstract
2928 - Immune checkpoint inhibitors in a cohort of 206 metastatic uveal melanomas patients
Presenter: Mathilde Saint-Ghislain
Session: Poster Display session 3
Resources:
Abstract
1235 - Incidence and survival of Uveal Melanoma occurring as single cancer versus its occurrence as a first or second primary neoplasm
Presenter: Ahmad Alfaar
Session: Poster Display session 3
Resources:
Abstract
3615 - Validation of a Clinicopathological and Gene Expression Profile (CP-GEP) Model for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
Presenter: Evalyn Mulder
Session: Poster Display session 3
Resources:
Abstract
1793 - External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC) using the Surveillance, Epidemiology and End Results (SEER) Program
Presenter: Angelina Tjokrowidjaja
Session: Poster Display session 3
Resources:
Abstract
4278 - Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts).
Presenter: Ines Pires da Silva
Session: Poster Display session 3
Resources:
Abstract